RBX-2660 for the Treatment of Recurrent Clostridium Difficile Infection – third line
RBX-2660 is a therapy under development for recurrent CDI. It is a non-antibiotic therapy that consists of human-derived microorganisms (microbiota suspension). It is administered directly into the patient’s intestine through the rectum as an enema. RBX-2660 has the potential to treat patients re-infected by C. difficile that currently have limited treatment options available and are at risk of serious health consequences.
Cefiderocol for severe gram-negative infections
Cefiderocol is a new drug to treat severe infections, which are caused by a particular group of bacteria called gram-negative bacteria, which are increasingly resistant to many antibiotics. Infections such as pneumonia, complicated urinary tract infections and bloodstream infections, are serious infections and a huge problem for the NHS. They prolong patient stay in hospital …
Plazomicin for treatment of multi-drug resistant Gram-negative Enterobacteriaceae infections
Hospital acquired infections, such as pneumonia, complicated urinary tract infections and bloodstream infections, are serious infections and a huge problem for the NHS. They prolong patients’ stay in hospital and increase health costs. These infections are frequently caused by types of bacteria that are becoming increasingly resistant to commonly prescribed antibiotics. Resistance to antibiotics is …
Cadazolid for treatment of Clostridium difficile-associated diarrhoea
Clostridium difficile is a bacterium that infects the gut and causes diarrhoea. It usually affects people who have recently taken antibiotics and it can cause serious bowel problems if left untreated. The bacterium is easily spread by direct contact with infected people or surfaces. Cadazolid is a new antibiotic that is taken by mouth as …